Literature DB >> 12620908

Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.

Shawn D Safford1, Dominique Goyeau, Alex J Freemerman, Rex Bentley, Mary Lou Everett, Paul E Grundy, Michael A Skinner.   

Abstract

BACKGROUND: The aim of this study was to more precisely map the region of 16q loss of heterozygosity (LOH) in Wilms' tumors and to examine the expression of putative tumor suppressor.
METHODS: We performed polymerase chain reaction-based LOH analysis on the 185 sample pairs from 21 to 80 megabases (Mb) on chromosome 16q. Expression of two candidate tumor suppressor genes located within the identified consensus region of 16q LOH was examined by immunohistochemistry.
RESULTS: We identified 16q LOH in 7 (4%) of 185 Wilms' tumors not previously thought to demonstrate such genetic loss. The smallest common region of genetic loss was located between 67.3 and 74.0 Mb on chromosome 16. Within this 6.7-Mb region, there reside only three recognized tumor suppressor genes: E-cadherin, P-cadherin, and E2F4. E-cadherin demonstrates statistically significantly reduced expression in Wilms' tumors with 16q LOH.
CONCLUSIONS: We have localized the consensus region of 16q LOH in Wilms' tumor to a 6.7-Mb locus and have identified three candidate Wilms' tumor suppressor genes within this narrowed region. Our data support E-cadherin as a candidate tumor suppressor gene in Wilms' tumor; however, further studies are needed to definitively prove its role as the tumor suppressor gene associated with 16q LOH.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620908     DOI: 10.1245/aso.2003.03.038

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  8 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

2.  Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Authors:  Isao Hirano; Satoki Nakamura; Daisuke Yokota; Takaaki Ono; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Shinjo; Kazunori Ohnishi
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

Review 3.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

4.  Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.

Authors:  Linda Holmquist Mengelbier; Jenny Karlsson; David Lindgren; Ingrid Øra; Margareth Isaksson; Ildiko Frigyesi; Attila Frigyesi; Johannes Bras; Bengt Sandstedt; David Gisselsson
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

Review 5.  PHLiPPing the switch on Akt and protein kinase C signaling.

Authors:  John Brognard; Alexandra C Newton
Journal:  Trends Endocrinol Metab       Date:  2008-05-27       Impact factor: 12.015

6.  Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization.

Authors:  Lesleyann Hawthorn; John K Cowell
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

Review 7.  Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.

Authors:  Samuel J Rodgers; Daniel T Ferguson; Christina A Mitchell; Lisa M Ooms
Journal:  Biosci Rep       Date:  2017-02-10       Impact factor: 3.840

8.  Integrated Analysis of Ulcerative Colitis Revealed an Association between PHLPP2 and Immune Infiltration.

Authors:  Ting Li; Weidong Liu; Wenjia Hui; Tian Shi; Huan Liu; Yan Feng; Feng Gao
Journal:  Dis Markers       Date:  2022-03-16       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.